Welcome!

News Feed Item

Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings

BOSTON, MA -- (Marketwired) -- 04/22/14 -- The Eventide Gilead Fund (NASDAQ: ETGLX) and the Eventide Healthcare & Life Sciences Fund (NASDAQ: ETAHX) were both named "Category Kings" by the Wall Street Journal for the one-year period ending March 31, 2014. The award recognizes the top 10 funds in each category for total return for the one-year period. The Eventide Gilead Fund ranked #2 in Mid-Cap Growth out of 375 funds and the Eventide Healthcare & Life Sciences Fund ranked #6 in Health & Biotech out of 86 funds.

Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment advisor practicing values-based investing. Eventide CEO Robin John commented on the awards, "Eventide strives to invest in companies that not only excel at creating shareholder value -- as the awards highlight -- but also stakeholder value: for customers, employees, and society. We believe that by targeting companies focusing on broad stakeholder value creation, we have been able to generate this outperformance over the past year and since inception."

Over the period, the Eventide Gilead Fund generated a total return of +44.36% compared to the Russell Mid-Cap Growth index return of +24.22% and the S&P 500 return of +21.86%, and outperformance of each by +20.14% and +22.5%, respectively; the Eventide Healthcare & Life Sciences Fund generated a total return of +49.11% compared to the Healthcare Blended Index of +32.44% and the S&P 500 return of +21.86%, an outperformance of each by +16.67% and +27.25%, respectively.

The following tables show the Funds' performance since inception:

----------------------------------------------------------------------------
                                      3 year      5 year    Since inception
 As of 3/31/2014    YTD    1 year   annualized  annualized    (07/08/2008)
                  return   return     return      return   annualized return
----------------------------------------------------------------------------
Eventide Gilead
Fund                6.59%   44.36%      21.48%      26.61%            18.24%
----------------------------------------------------------------------------
Russell Mid-Cap
Growth Total        2.04%   24.22%      13.52%      24.73%            10.79%
Return Index
----------------------------------------------------------------------------
S&P 500 Total
Return Index        1.81%   21.86%      14.66%      21.16%             9.35%
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                           Since inception
     As of 3/31/2014        YTD return    1 year return     (12/27/2012)
                                                          annualized return
----------------------------------------------------------------------------
Eventide Healthcare &
Life Sciences Fund                 8.87%         49.11%               57.25%
----------------------------------------------------------------------------
Healthcare Blended Index           0.53%         32.44%               40.04%
----------------------------------------------------------------------------
S&P 500 Total Return
Index                              1.81%         21.86%               27.37%
----------------------------------------------------------------------------

Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the funds' prospectus for more information regarding the funds' fees and expenses. Eventide Gilead Fund performance shown is for No-load Class shares and the Eventide Healthcare & Life Sciences Fund performance shown is for A Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

Eventide Gilead Fund expenses: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses (excluding certain fees and expenses) at 1.42% at least until October 31, 2014. Eventide Healthcare & Life Sciences Fund expenses: Gross Expenses 9.56%; Net Expenses 1.69%. The advisor has agreed to maintain the Fund's total annual operating expenses (excluding certain fees and expenses) at 1.43% at least until October 31, 2014.

As of March 31, 2014, the Eventide Gilead Fund had $630.2M in net assets and the Eventide Healthcare & Life Sciences Fund had $97.1M in net assets.

Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. The Eventide Gilead Fund ranked #9 out of 342 Mid-Cap Growth funds (Lipper data) for the 3-yr period based on total returns and #15 out of 288 Mid-Cap Growth funds (Lipper data) for the 5-yr period based on total returns.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. These indexes are not investment products available for purchase.

Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

An investor should consider the Funds' investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds' prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Fund Contact:
Jason Myhre
877-771-EVEN (3836)

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...